The company raised its fiscal 2026 financial outlook, expecting over $50 billion in specialty revenue. Bank of America increased its price target to $240, maintaining a buy rating. Analysts highlight the company's above-average financial growth, strong earnings surprise history, and strategic progress in medical distribution and specialty therapies. The stock price recently closed higher following the positive guidance update and analyst upgrades.